29 April 2026 -  We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis whose symptoms are not controlled by existing treatments.

Our recommendation was published today in final draft guidance. Rozanolixizumab (also known as Rystiggo and made by UCB Pharma) could help around 800 adults in England. It aims to reduce symptoms and improve day‑to‑day quality of life.

Read NICE press release